Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Efungumab, a monoclonal antibody exhibiting antifungal properties, specifically targets HSP 90 to inhibit a conformational alteration crucial for fungal survival. It is employed in investigations concerning invasive candidiasis (IC) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Efungumab, a monoclonal antibody exhibiting antifungal properties, specifically targets HSP 90 to inhibit a conformational alteration crucial for fungal survival. It is employed in investigations concerning invasive candidiasis (IC) [1]. |
In vivo | Efungumab (2 mg/kg, i.p., once daily for three consecutive days) significantly reduced the average number of fungal colonies on the organs and increased the incidence of negative liver biopsy results in the CD1 mouse model of systemic Candida albicans infection [2]. |
Molecular Weight | N/A |
CAS No. | 762260-74-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Efungumab 762260-74-2 inhibitor inhibit